Episode 19: A Between the Biotech Waves Conversation with JeanFrancois Formela, Partner at Atlas Venture & multi-biotech company founder

1

Introduction

00:00 • 2min

2

Xelixis - What Are the Early Investments?

02:16 • 5min

3

The Challenges of RNA Biology in the Human Genome

07:44 • 3min

4

Target Selection Is the Key Fundamental Elements of Success, Right?

10:19 • 2min

5

Investing in a Drug Development Company Is a Good Idea, Right?

12:28 • 4min

6

The Biotech Industry, You Know, Is There Not Enough Money?

16:01 • 4min

7

Is It a Tactic Challenge?

19:35 • 3min

8

Biotech

22:15 • 3min

9

CRISPR-Cas9 - What Was Your Thinking?

25:07 • 4min

10

Is It Possible That Chris Prokasten Had Been Found or Identified 15 Years Ago?

28:54 • 2min

11

How Did You Think About Permanently Modifying Human DNA?

30:43 • 3min

12

Is CRISPR-Cas9 Really a Drug?

34:06 • 5min

13

Deliver Is a D Word, Right?

39:02 • 2min

14

Is There a Future for AV?

40:34 • 2min

15

Gene Therapy, Gene Editing - Is There a Catch-Up?

42:46 • 3min

16

Is There a Continuous Evolution in the Genome Editing Sector?

46:06 • 4min